Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04381832 · ClinicalTrials.gov registry record · Phase 1
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
A Phase 1 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 173
- Enrollment target
NCT04381832: Completed Phase 1 study, sponsored by Arcus Biosciences.
NCT04381832 is a Phase 1 study that has completed, run by Arcus Biosciences. The registered enrollment target is 173 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (188% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04381832, a Phase 1 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 173 participants
- Enrollment target
Study Summary
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
Primary Outcome
ORR defined as the composite proportion of participants with a Prostate Specific Antigen (PSA) and/or radiographic complete response (CR) and partial response (PR) determined by the investigator according to the Prostate Cancer Working Group 3 (PCWG3) criteria
Interventions
- DRUG Docetaxel
- DRUG Zimberelimab
- DRUG Quemliclustat
- DRUG Enzalutamide
- DRUG Etrumadenant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2020-07-07 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 1 |
What the finished NCT04381832 record still lists
NCT04381832 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (188% higher).
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT04381832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04381832 about?
NCT04381832 is a clinical study titled "Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer". This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
What is the current status of trial NCT04381832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 173 participants. The study started on 2020-07-07. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT04381832?
The interventions under investigation include: Docetaxel (DRUG), Zimberelimab (DRUG), Quemliclustat (DRUG), Enzalutamide (DRUG), Etrumadenant (DRUG).
Who is sponsoring clinical trial NCT04381832?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04381832's enrollment target sits among peer trials
173 324th of 2000 higher than 1,677 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI